PML control of cytokine signaling

Cytokine and Growth Factor Reviews

Volumn 25, Issue 5, 2014, Pages 551-561

  Maarifi, Ghizlane ^a   Chelbi Alix, Mounira K ^a   Nisole, Sébastien ^a  

^a Centre Universitaire des Saints Pères   (France)

Author keywords

Cytokine signaling; Interferon; Nuclear bodies; PML; TRIM19

Indexed keywords

BETA INTERFERON; CRYOPYRIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; PMLIV PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; SMAD3 PROTEIN; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIPARTITE MOTIF PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; INFLAMMASOME; ISOPROTEIN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CELL DEATH; CELL NUCLEUS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPLASM; HUMAN; INFECTION RESISTANCE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MACROPHAGE; NONHUMAN; PML GENE; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSACTIVATION; VIRUS INFECTION; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; CYTOKINES; HUMANS; INFLAMMASOMES; NUCLEAR PROTEINS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84908314558     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.04.008     Document Type: Review

References (87)

1. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., et al. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 1999, 147:221-234.
2. Wang Z.G., Delva L., Gaboli M., Rivi R., Giorgio M., Cordon-Cardo C., et al. Role of PML in cell growth and the retinoic acid pathway. Science 1998, 279:1547-1551.
3. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998, 20:266-272.
4. Lin H.K., Bergmann S., Pandolfi P.P. Cytoplasmic PML function in TGF-beta signalling. Nature 2004, 431:205-211.
5. de The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990, 347:558-561.
6. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., et al. The tripartite motif family identifies cell compartments. EMBO J 2001, 20:2140-2151.
7. Nisole S., Stoye J.P., Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005, 3:799-808.
8. Jensen K., Shiels C., Freemont P.S. PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001, 20:7223-7233.
9. Nisole S., Maroui M.A., Mascle X.H., Aubry M., Chelbi-Alix M.K. Differential roles of PML isoforms. Front Oncol 2013, 3:125.
10. Cheng X., Kao H.Y. Post-translational modifications of PML: consequences and implications. Front Oncol 2012, 2:210.
11. Schmitz M.L., Grishina I. Regulation of the tumor suppressor PML by sequential post-translational modifications. Front Oncol 2012, 2:204.
12. Lallemand-Breitenbach V., Zhu J., Puvion F., Koken M., Honore N., Doubeikovsky A., et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001, 193:1361-1371.
13. Pampin M., Simonin Y., Blondel B., Percherancier Y., Chelbi-Alix M.K. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol 2006, 80:8582-8592.
14. El Mchichi B., Regad T., Maroui M.A., Rodriguez M.S., Aminev A., Gerbaud S., et al. SUMOylation promotes PML degradation during encephalomyocarditis virus infection. J Virol 2010, 84:11634-11645.
15. Shen T.H., Lin H.K., Scaglioni P.P., Yung T.M., Pandolfi P.P. The mechanisms of PML-nuclear body formation. Mol Cell 2006, 24:331-339.
16. Kamitani T., Kito K., Nguyen H.P., Wada H., Fukuda-Kamitani T., YE T. Identification of three major sentrinization sites in PML. J Biol Chem 1998, 273(41):26675-26682.
17. Galisson F., Mahrouche L., Courcelles M., Bonneil E., Meloche S., Chelbi-Alix M.K., et al. A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells. Mol Cell Proteomic 2011, 10:M110004796.
18. Rabellino A., Carter B., Konstantinidou G., Wu S.Y., Rimessi A., Byers L.A., et al. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res 2012, 72:2275-2284.
19. Zhong S., Muller S., Ronchetti S., Freemont P.S., Dejean A., Pandolfi P.P. Role of SUMO-1-modified PML in nuclear body formation. Blood 2000, 95:2748-2752.
20. Chelbi-Alix M.K., Pelicano L., Quignon F., Koken M.H., Venturini L., Stadler M., et al. Induction of the PML protein by interferons in normal and APL cells. Leukemia 1995, 9:2027-2033.
21. Goodbourn S., Didcock L., Randall R.E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000, 81:2341-2364.
22. Chelbi-Alix M.K., Wietzerbin J. Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 2007, 89(6-7):713-718.
23. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008, 8:559-568.
24. Stadler M., Chelbi-Alix M.K., Koken M.H., Venturini L., Lee C., Saib A., et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 1995, 11:2565-2573.
25. Kim T.K., Lee J.S., Oh S.Y., Jin X., Choi Y.J., Lee T.H., et al. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells. Cancer Res 2007, 67:11133-11140.
26. Dror N., Rave-Harel N., Burchert A., Azriel A., Tamura T., Tailor P., et al. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J Biol Chem 2007, 282:5633-5640.
27. Hubackova S., Krejcikova K., Bartek J., Hodny Z. Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J Biol Chem 2012, 287:26702-26714.
28. Gao C., Ho C.C., Reineke E., Lam M., Cheng X., Stanya K.J., et al. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation. Mol Cell Biol 2008, 28:5658-5667.
29. Cheng X., Liu Y., Chu H., Kao H.Y. Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha). J Biol Chem 2012, 287:23356-23367.
30. Heuser M., van der Kuip H., Falini B., Peschel C., Huber C., Fischer T. Induction of the pro-myelocytic leukaemia gene by type I and type II interferons. Mediat Inflamm 1998, 7:319-325.
31. Bernardi R., Papa A., Pandolfi P.P. Regulation of apoptosis by PML and the PML-NBs. Oncogene 2008, 27:6299-6312.
32. Crowder C., Dahle O., Davis R.E., Gabrielsen O.S., Rudikoff S. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 2005, 105:1280-1287.
33. Wu W.S., Xu Z.X., Hittelman W.N., Salomoni P., Pandolfi P.P., Chang K.S. Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem 2003, 278:12294-12304.
34. Lunardi A., Gaboli M., Giorgio M., Rivi R., Bygrave A., Antoniou M., et al. A role for PML in innate immunity. Gene Cancer 2011, 2:10-19.
35. Ohgiya D., Matsushita H., Onizuka M., Nakamura N., Amaki J., Aoyama Y., et al. Association of promyelocytic leukemia protein with expression of IL-6 and resistance to treatment in multiple myeloma. Acta Haematol 2012, 128:213-222.
36. Lo Y.H., Huang Y.W., Wu Y.H., Tsai C.S., Lin Y.C., Mo S.T., et al. Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human. Blood 2013, 121:3185-3194.
37. Haneklaus M., O'Neill L.A., Coll R.C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013, 25:40-45.
38. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013, 13:397-411.
39. Giorgi C., Ito K., Lin H.K., Santangelo C., Wieckowski M.R., Lebiedzinska M., et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 2010, 330:1247-1251.
40. Dowling J.K., Becker C.E., Bourke N.M., Corr S.C., Connolly D.J., Quinn S.R., et al. Promyelocytic Leukemia Protein Interacts with the Apoptosis-associated Speck-like Protein to Limit Inflammasome Activation. J Biol Chem 2014, 289:6429-6437.
41. Bonilla W.V., Pinschewer D.D., Klenerman P., Rousson V., Gaboli M., Pandolfi P.P., et al. Effects of promyelocytic leukemia protein on virus-host balance. J Virol 2002, 76:3810-3818.
42. Chelbi-Alix M.K., Quignon F., Pelicano L., Koken M.H.M., de The H. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 1998, 72:1043-1051.
43. Djavani M., Rodas J., Lukashevich I.S., Horejsh D., Pandolfi P.P., Borden K.L., et al. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J Virol 2001, 75:6204-6208.
44. El Asmi F., Maroui M.A., Dutrieux J., Blondel D., Nisole S., Chelbi-Alix M.K. Implication of PMLIV in both intrinsic and innate immunity. PLoS Pathog 2014, 10:e1003975.
45. Blondel D., Kheddache S., Lahaye X., Dianoux L., Chelbi-Alix M.K. Resistance to rabies virus infection conferred by the PMLIV isoform. J Virol 2010, 84:10719-10726.
46. Blondel D., Regad T., Poisson N., Pavie B., Harper F., Pandolfi P.P., et al. Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies. Oncogene 2002, 21:7957-7970.
47. Chee A.V., Lopez P., Pandolfi P.P., Roizman B. Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol 2003, 77:7101-7105.
48. Regad T., Saib A., Lallemand-Breitenbach V., Pandolfi P.P., de The H., Chelbi-Alix M.K. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 2001, 20:3495-3505.
49. Maroui M.A., Pampin M., Chelbi-Alix M.K. Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies. J Virol 2011, 85:13164-13173.
50. Tavalai N., Papior P., Rechter S., Leis M., Stamminger T. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J Virol 2006, 80:8006-8018.
51. Kyratsous C.A., Silverstein S.J. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J Virol 2009, 83:4262-4274.
52. Everett R.D., Chelbi-Alix M.K. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 2007, 89(6-7):819-830.
53. Geoffroy M.C., Chelbi-Alix M.K. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res 2011, 31:145-158.
54. El Bougrini J., Dianoux L., Chelbi-Alix M.K. PML positively regulates interferon gamma signaling. Biochimie 2011, 93:389-398.
55. Choi Y.H., Bernardi R., Pandolfi P.P., Benveniste E.N. The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc Natl Acad Sci U S A 2006, 103:18715-18720.
56. Ulbricht T., Alzrigat M., Horch A., Reuter N., von Mikecz A., Steimle V., et al. PML promotes MHC class II gene expression by stabilizing the class II transactivator. J Cell Biol 2012, 199:49-63.
57. Herzer K., Hofmann T.G., Teufel A., Schimanski C.C., Moehler M., Kanzler S., et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009, 69:855-862.
58. Koken M.H., Reid A., Quignon F., Chelbi-Alix M.K., Davies J.M., Kabarowski J.H., et al. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci U S A 1997, 94:10255-10260.
59. Xu D., Holko M., Sadler A.J., Scott B., Higashiyama S., Berkofsky-Fessler W., et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009, 30:802-816.
60. Ozato K. PLZF outreach: a finger in interferon's pie. Immunity 2009, 30:757-758.
61. Wormald S., Hilton D.J. Inhibitors of cytokine signal transduction. J Biol Chem 2004, 279:821-824.
62. Hertzog P.J., Williams B.R. Fine tuning type I interferon responses. Cytokine Growth Factor Rev 2013, 24:217-225.
63. Liu B., Gross M., ten Hoeve J., Shuai K. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proc Natl Acad Sci U S A 2001, 98:3203-3207.
64. Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D., et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A. 1998, 95:10626-10631.
65. Rytinki M.M., Kaikkonen S., Pehkonen P., Jaaskelainen T., Palvimo J.J. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 2009, 66:3029-3041.
66. Saitoh T., Tun-Kyi A., Ryo A., Yamamoto M., Finn G., Fujita T., et al. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 2006, 7:598-605.
67. Reichelt M., Wang L., Sommer M., Perrino J., Nour A.M., Sen N., et al. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog 2011, 7:e1001266.
68. Yang K., Shi H.X., Liu X.Y., Shan Y.F., Wei B., Chen S., et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol 2009, 182:3782-3792.
69. Lin H.K., Bergmann S., Pandolfi P.P. Deregulated TGF-beta signaling in leukemogenesis. Oncogene 2005, 24:5693-5700.
70. Carracedo A., Ito K., Pandolfi P.P. The nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin Cell Biol 2011, 23:360-366.
71. Seo S.R., Ferrand N., Faresse N., Prunier C., Abecassis L., Pessah M., et al. Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol Cell 2006, 23:547-559.
72. Faresse N., Colland F., Ferrand N., Prunier C., Bourgeade M.F., Atfi A. Identification of PCTA, a TGIF antagonist that promotes PML function in TGF-beta signalling. EMBO J 2008, 27:1804-1815.
73. Ettahar A., Ferrigno O., Zhang M.Z., Ohnishi M., Ferrand N., Prunier C., et al. Identification of PHRF1 as a tumor suppressor that promotes the TGF-beta cytostatic program through selective release of TGIF-driven PML inactivation. Cell Rep 2013, 4:530-541.
74. Pan D., Zhu Q., Luo K. SnoN functions as a tumour suppressor by inducing premature senescence. EMBO J 2009, 28:3500-3513.
75. Tang M.K., Liang Y.J., Chan J.Y., Wong S.W., Chen E., Yao Y., et al. Promyelocytic leukemia (PML) protein plays important roles in regulating cell adhesion, morphology, proliferation and migration. PLoS ONE 2013, 8:e59477.
76. Moreno R., Sobotzik J.M., Schultz C., Schmitz M.L. Specification of the NF-kappaB transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of IKK epsilon. Nucleic Acids Res 2010, 38:6029-6044.
77. Renner F., Moreno R., Schmitz M.L. SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death. Mol Cell 2010, 37:503-515.
78. Jin G., Wang Y.J., Lin H.K. Emerging cellular functions of cytoplasmic PML. Front Oncol 2013, 3:147.
79. Versteeg G.A., Rajsbaum R., Sanchez-Aparicio M.T., Maestre A.M., Valdiviezo J., Shi M., et al. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity 2013, 38:384-398.
80. Rajsbaum R., Garcia-Sastre A., Versteeg G.A. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 2014, 426:1265-1284.
81. Kawai T., Akira S. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med 2011, 3:513-527.
82. McNab F.W., Rajsbaum R., Stoye J.P., O'Garra A. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 2011, 23:46-56.
83. Marin I. Origin and diversification of TRIM ubiquitin ligases. PLoS ONE 2012, 7:e50030.
84. Meroni G., Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. BioEssays: News Rev Mol Cell Dev Biol 2005, 27:1147-1157.
85. Liang Q., Deng H., Li X., Wu X., Tang Q., Chang T.H., et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J Immunol 2011, 187:4754-4763.
86. Zou W., Zhang D.E. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 2006, 281:3989-3994.
87. Van Damme E., Laukens K., Dang T.H., Van Ostade X. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci 2010, 6:51-67.